Glaukos president sells 60,000 shares after exercising options
GLAUKOS Corp president and COO Joseph E. Gilliam reported multiple option exercises and related stock sales for GKOS on 2026-08-11.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
GLAUKOS Corp president and COO Joseph E. Gilliam reported multiple option exercises and related stock sales for GKOS on 2026-08-11. He exercised options covering 60,000 shares of Common Stock and acquired an equal number of shares, then sold 60,000 Common shares in two open-market transactions at weighted average prices of $178.89 and $180.49 per share. He also continues to hold 41,983 restricted stock units and 225 stock units from the Employee Stock Purchase Plan, which remain unvested or undelivered.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F4 | 20,000 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) F5, F6 | 20,000 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) F7 | 10,000 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) F8 | 10,000 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 10,000 | $48.46 | $485K |
| Exercise | Common Stock F1 | 20,000 | $55.18 | $1.10M |
| Exercise | Common Stock F1 | 20,000 | $55.18 | $1.10M |
| Exercise | Common Stock F1 | 10,000 | $48.46 | $485K |
| Sale | Common Stock F2, F1 | 27,963 | $178.89 | $5.00M |
| Sale | Common Stock F3, F1 | 32,037 | $180.49 | $5.78M |
Footnotes (8)
- F1. Includes 41,983 restricted stock units that have not yet vested or been delivered to the Reporting Person and and 225 stock units purchased by the Reporting Person through the Issuer's Employee Stock Purchase Plan.
- F2. This transaction was executed in multiple trades at prices ranging from $178.60 to $179.58). The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3. This transaction was executed in multiple trades at prices ranging from $179.68 to $180.60). The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4. Represents a portion of an option to purchase shares of common stock previously granted by the Issuer on March 24, 2022, the vesting of which was subject to the Issuer's achievement of certain pre-determined operational targets over a multi-year performance period.
- F5. Represents a portion of an option to purchase shares of common stock previously granted by the Issuer to the Reporting Person on March 24, 2022 in connection with his promotion to President and Chief Operating Officer, the vesting of which was subject to the Issuer's achievement of certain multi-year performance goals.
- F6. Total amount reported has been adjusted to correct a typographical error made in a Form 4 report filed by the Reporting Person on March 17, 2025, in which 13,721 stock options earned were erroneously reported as 13,271 stock options.
- F7. These options vest over four years from the grant date, with 25% vesting on the first anniversary of the grant date and the remaining amount vesting in equal monthly installments over the following three years.
- F8. Represents a portion of an option to purchase shares of common stock previously granted by the Issuer on March 22, 2023, the vesting of which was subject to the Issuer's achievement of certain pre-determined operational targets over a multi-year performance period.
Key Figures
Key Terms
restricted stock units financial
Employee Stock Purchase Plan financial
weighted average price financial
multi-year performance period financial
performance goals financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did GLAUKOS Corp (GKOS) report for Joseph E. Gilliam?
What stock options did Joseph E. Gilliam exercise in this GKOS Form 4?
Does the GLAUKOS (GKOS) Form 4 show any remaining unvested equity for Joseph E. Gilliam?
Were Joseph E. Gilliam’s GKOS stock sales under a Rule 10b5-1 trading plan?
What performance conditions were tied to Gilliam’s GKOS option grants?
AI-generated analysis. How Rhea-AI works. Not financial advice.